Periocular injection a feasible route for CNV treatment

Article

The size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid but not into the retina.

The size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid but not into the retina, according to a report published in the February issue of the Journal of Ocular Pharmacology and Therapeutics.

Anna Demetriades and colleagues from the John Hopkins University, School of Medicine, Baltimore, US conducted a study to investigate the penetration of various proteins into a mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein.

Following a periocular injection of AdsFlt-1.10, AdTGF ß.10 or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor- ß (TGF- ß) were not significantly different from scleral levels, and choroidal levels of sFlt-1 were only moderately reduced from scleral levels. However, retinal levels of each of these proteins were low compared with choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked two hours after injection and returned to baseline between six and 24 hours. Peak levels in the retina were 8.6% of peak choroidal levels.

This study suggests that periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but further investigations are required before they could be considered for the treatment of retinal disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
© 2025 MJH Life Sciences

All rights reserved.